Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
After Settling on October 2019 Re-Pricing, When Will Govt Reveal New Drug Prices?
Now that the Japanese government has made up its mind to conduct an ad-hoc drug price revision associated with the planned consumption tax hike in October 2019, all eyes are turning to when it will announce the new price list,…
To read the full story
Related Article
- MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head
January 16, 2019
- New NHI Prices Will Be Announced “at Most Appropriate Time”: MHLW Official
January 10, 2019
- JMA Chief Pushes September 2019 Drug Price Announcement for Ad-Hoc Revision
December 27, 2018
- March Announcement of NHI Price List “Not an Option”, Says Wholesaler Group
December 25, 2018
REGULATORY
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…